title: The likelihood of having a serum PSA level of ≥2.5 or ≥4.0 ng ml(-1) according to obesity in a screened Korean population.
abstract: This study aimed to determine if lower serum total prostate-specific antigen (PSA) levels in obese Korean men affect prostate cancer (PCa) screening, as an increased body mass index (BMI) is inversely associated with the PSA level. Between March 2007 and December 2012, 22 208 native Korean men who were eligible to receive a serum PSA test were recruited. Logistic regression was used to estimate the odds of an 'abnormal' PSA (≥2.5 or ≥4.0 ng ml(-1)) in these men (age: 45-75 years, PSA <10 ng ml(-1)) based on BMI, which was categorized as normal (BMI <25 kg m(-2)) and obese (BMI ≥25 kg m(-2)). In all, 20 509 men (92.3%) were included in the study after applying the inclusion criteria. After controlling for age, there was a statistically significant trend towards a lower likelihood of having a serum PSA level ≥2.5 ng ml(-1) with an increased BMI, with obese men having an 18% lower likelihood (odds ratio: 0.823, 95% confidence interval: 0.743-0.912; P<0.001) compared to men with a normal BMI. Obese men were approximately 82% as likely to have a PSA level ≥2.5 ng ml(-1) as men with a normal BMI. These results might affect PCa screening using serum total PSA. Further studies are needed to better define these results in clinical biopsy practice.
authors.forename: Won Jae
authors.initials: WJ
authors.lastname: Yang
mesh_terms: D006801:Humans; D016013:Likelihood Functions; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D017430:Prostate-Specific Antigen / Q000097:blood*; D056910:Republic of Korea
chemical_list: D017430:Prostate-Specific Antigen
references.citation: Prostate. 1999 Sep 1;40(4):261-8
references.pmid: 10420155
references.citation: Urology. 2006 Jul;68(1):85-8
references.pmid: 16806412
references.citation: World Rev Nutr Diet. 2005;94:1-12
references.pmid: 16145245
references.citation: Prostate. 2010 Feb 1;70(2):120-5
references.pmid: 19739130
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):345-53
references.pmid: 11319175
references.citation: Eur Urol. 2013 May;63(5):800-9
references.pmid: 23219374
references.citation: Urology. 2008 May;71(5):787-91
references.pmid: 18267334
references.citation: Urology. 2010 Oct;76(4):919-22
references.pmid: 20303152
references.citation: BJU Int. 2009 Nov;104(10):1457-61
references.pmid: 19522868
references.citation: N Engl J Med. 2003 Apr 24;348(17):1625-38
references.pmid: 12711737
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):63-9
references.pmid: 17179486
references.citation: J Urol. 2009 Dec;182(6):2646-51
references.pmid: 19836806
references.citation: JAMA. 2007 Nov 21;298(19):2275-80
references.pmid: 18029831
references.citation: N Engl J Med. 2004 May 27;350(22):2239-46
references.pmid: 15163773
references.citation: Cancer. 2007 Feb 15;109(4):675-84
references.pmid: 17211863
references.citation: Ann Oncol. 2012 Jul;23(7):1665-71
references.pmid: 22228452
references.citation: Asian J Androl. 2011 Jul;13(4):640-3
references.pmid: 21170076
references.citation: Urology. 2004 Apr;63(4):727-31
references.pmid: 15072889
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1977-83
references.pmid: 17035408
references.citation: JAMA. 1997 May 14;277(18):1452-5
references.pmid: 9145717
references.citation: Asian J Androl. 2011 Jul;13(4):574-8
references.pmid: 21552284